Study of blood thickness in Waldenström’s disease
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study looks at “hyperviscosity,” meaning very thick blood, in people with Waldenström macroglobulinemia (WM). Your results may help doctors better understand who needs treatment and what tests should be used, even if thick blood is not found.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Waldenström macroglobulinemia (WM).
- Your care team expects you may need to start treatment soon (first-line or later treatment).
- Your blood protein test shows a “monoclonal” protein level above 15 grams per liter.
- You agree to have a hyperviscosity assessment (the study’s blood thickness evaluation).
- You can and will sign informed consent to join the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at a blood test called circulating tumor DNA, measured after 6 months of treatment, to see how well it predicts outcomes in people with Waldenström macroglobulinemia. It may help doctors better judge who is responding and who may need treatment adjustments earlier.
This study looks at genetic and other traits of tumor/blood cells in adults with specific blood conditions who have fevers with unclear cause plus symptoms like rash or joint pain. The goal is to better understand what drives these “hyperinflammatory” reactions and how to tell them apart from other illnesses.
This study follows people with certain slow-growing blood cancers (CLL/SLL, LPL/WM, and related conditions) to understand how they progress and what leads to needing treatment. It may help doctors predict changes over time and plan care more effectively.
This study is a registry that collects information about adults with certain IgM-related blood conditions. It may help doctors better understand these illnesses and improve future care.
This Phase 2 study tests whether the combination of venetoclax and rituximab works better for Waldenström’s macroglobulinemia (WM) than expected from standard approaches. It is for adults with WM who have symptoms or organ/health problems caused by the disease.
This trial tests a combination of three drugs (pirtobrutinib, venetoclax, and rituximab) for people newly diagnosed with Waldenstrom's macroglobulinemia who have not had treatment before and need therapy for their symptoms.
Hear when a new Waldenstrom Macroglobulinemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.